have been reported to be cytotoxic to tumour cells in vitro and in vivo. For that reason they are evaluated as a new modality for cancer treatment. In the present study we have quantified the effect of treatment with multifocal HESW on tumour blood flow and energy status. Blood flow and adenosine triphosphate (ATP) concentration were investigated simultaneously in tumour and adjacent tissue of six treated and six untreated amelanotic hamster melanomas (A-Mel-3) at 3, 12 or 24 h after multifocal application of HESW. '4C-iodoantipyrine autoradiography for blood flow measurements and quantitative ATP imaging bioluminescence were employed. Following treatment, tumour blood flow and ATP concentration were significantly reduced, as compared to control, over the entire period of observation. Three hours after HESW, blood flow and ATP concentration were at the background level. In adjacent tissue, blood flow and ATP concentration were distinctly diminished. We therefore conclude that multifocal HESW induce a breakdown of tumour-, and adjacent tissue perfusion which is accompanied by a significant decrease of intracellular ATP concentration.
The clinical introduction of Extracorporeal Shock Wave Lithotripsy (ESWL) in 1980 has changed the conventional methods for treatment of renal and ureteric calculi (Chaussy, 1988; Lingeman et al., 1989) . Initially, it has been presumed that ESWL disintegrates calculi without any significant effect on the surrounding tissues (Chaussy et al., 1982) . Subse- quently, detailed studies on acute and chronic adverse effects revealed morphologic and functional changes similar to renal contusion (Ackaert & Schr6der, 1989; Sakamoto et al., 1991; Smith et al., 1991) . Due to these adverse effects on soft tissue and the potential for noninvasive delivery of focused energy, the suitability of HESW for treatment of cancer has been suggested. Several studies have indicated that HESW are cytotoxic to tumour cells in vitro and in vivo (Russo et al., 1986; Kohri et al., 1990; Weiss et al., 1990; Clayman et al., 1991; Kaver et al., 1992) . Furthermore, the combination of HESW with experimental chemotherapy or immunotherapy results in an enhanced therapeutic efficacy (Oosterhof et al., 1990a; Gambihler & Delius, 1992) . The effects of HESW on tumours are dependent on the dose of HESW and the mode of administration (Oosterhof et al., 1990b; Weiss et al., 1990) .
Haemorrhage and destruction of vessels in tumours treated with HESW have pointed to the tumour vasculature as being a major target for HESW application (Hoshi et al., 1991 (Ribbert, 1904; Goetz et al., 1987; Jain, 1988) . Observations of the microvasculature have indicated that ischemia occurs immediately after application of HESW, which is caused in part by destruction of the vascular integrity (Brendel et al., 1987; Goetz et al., 1987; Hoshi et al., 1991) . This implies that exact knowledge about tumour perfusion following application of HESW would be of importance for the use of HESW as an adjuvant for cancer therapy. This is further supported by the fact that other non-surgical treatment modalities like radiotherapy, chemotherapy or hyperthermia are critically dependent on the blood supply of tumours and are also known to affect tumour blood flow (for a review, see Chaplin, 1991) .
It has been reported that tumour ischemia of at least 15 h is required to achieve complete tumour remission (Denekamp et al., 1983) . However, evaluation of blood flow alone does not yield conclusive information about cellular damage and viability. In contrast, a decrease of the cellular ATP level may be considered a sign of severe cellular damage. A healthy cell is dependent on sufficient energy production and a critical level of ATP. After death organic phosphates are broken down to inorganic phosphate (Atkinson, 1977) . Consequently, measurement of the phosphate status may be used to provide early information about metabolic disorders caused by treatment.
The purpose of this investigation was to quantify simultaneously the effects of multifocally applied HESW on blood flow and ATP concentration in solid tumours, and their adjacent tissue. In order to facilitate interpretation of the data with respect to the efficiency of this therapeutic approach, tumour growth following HESW application was examined.
Materials and methods

Animals and tumours
Experiments were performed on amelonotic melanoma AMel-3 tumours (Fortner et at., 1961) implanted into the depilated back of male Syrian Golden Hamsters (9-11 weeks old, 80-100 g body weight in the perspex tube. The skin flap was fixed to an external suspension arch with four sutures. As protection for the animal's body from the high pressure field, the tube was covered with 2 mm polystyrene on the inner and outer sides. The tube was submerged into a warm water bath (33-35°C) of the lithotripter with the water level 10 cm above the tumour. The tumour to be treated was randomly chosen and placed in the high pressure field by positioning it at the intersection of the two laser beams. The second tumour served as intraindividual control, at least 2 cm away from the centre of the HESW focus. Seven hundred HESW were applied multifocally at a rate of 100 per min with a discharge voltage of 20 kV and a condenser capacity of 80 nF. Multifocal application was employed in order to give a more equal distribution of HESW energy within the tumour tissue and adjacent tissue. For this purpose 200 HESW were focused on the tumour centre and another 500 HESW on five symmetric areas at the tumour border as shown in Figure 1 . Control animals for observation of tumour growth were placed in the same perspex tube, in the same water bath, for the same time, but not exposed to HESW.
Autoradiographic measurement of bloodflow Tumour blood flow was measured autoradiographically by the method described by Kety (1960) and Sakurada et al. (1978) using the tissue uptake of the inert and readily diffusible compound [4-N-methyl-'4C]-iodoantipyrine (IAP; NEC 712, Du Pont-NEN, Dreieich, Germany).
Animals were anesthetised and polyethylene catheters (Portex Ltd., Hythe, Kent, England) were inserted into the right carotid artery, vena cava superior and femoral artery. Forty pCi of IAP were dissolved in 0.55 ml of 0.9% saline and infused over 30s at a constant rate via the central venous catheter. Simultaneously, arterial blood samples for determination of blood concentration of IAP were collected every 4 s via the free-flowing catheter in the carotid artery, which was reduced to 35 mm length to minimise catheter smearing. Mean arterial blood pressure was registered conr J % I tinuously via the femoral artery. Thirty seconds after start of the infusion the tumours and adjacent skin were rapidly resected and immediately frozen in liquid nitrogen. Blood samples were weighted and the '4C activity was measured using a P-Counter (RackBeta 1219, LKB Wallac, Turku, Finland) . The concentration of IAP in each blood sample was calculated. Tumours were cut into serial cryosections alternately for blood flow measurements (thickness: 20 1tm), histology (5 pm) and ATP measurements (5 gm). Sections for histologic observation were stained with hematoxylin and eosin. Cryosections for ATP-bioluminescence were mounted on coverslips at -15°C, heat-inactivated at 90°C for 10 min and kept at -80°C until the determination of regional tissue ATP content described below.
Tissue radioactivity was visualised by exposure of the tumour sections together with calibrated '4C tissue standards (14C micro-scales; Amersham Buchler GmbH, Braunschweig, Germany) to Kodak NMC film (Eastman Kodak, Rochester, New York, USA) for 2 weeks. The autoradiogram of the '4C-IAP distribution on the processed film was recorded with a CCD-videocamera (XC-77; Sony, Cologne, Germany) on a macro-viewer with transmitted light and digitised (IBAS 2.0; Kontron GmbH, Eching, Germany). Grey levels of the autoradiographic images were measured in 8 sections of each tumour and adjacent tissue. Regional blood flow was calculated according to Sakurada et al. (1978) with the equation derived by Kety (1960) :
(1) Ci(T) represents the tissue concentration of IAP at time t = T, the end of 30 s infusion period. A is the tumour-blood partition coefficient for the A-Mel-3 tumour, which was determined according to the method of Sakurada et al. (1978) and found to be 0.86 (Gamarra, 1992) . Ca(t) is the arterial concentration of IAP at time t after the start of infusion. The specific blood flow F is derived from the parameter K using the following relationship: (Theodorsson-Norheim, 1986; 1987) . P-values smaller than 5% were regarded as significant.
Results
Measurement of bloodflow and A TP concentration Blood flow and ATP concentration in untreated and treated tumours and adjacent tissue are given in Table I . Adjacent normal tissue consisted of muscle, subcutaneous fat and skin. A wide inter-individual heterogeneity of blood flow and ATP concentration was observed in untreated tumours and untreated adjacent tissue. No differences were obtained between the three groups of controls. Untreated tumours and adjacent tissue revealed similar blood flow values of 35.8 ml 100 g-' minm and 34.9 ml 100 g' min' , respectively, whereas ATP concentration was higher in adjacent tissue (1.50 mM) than in tumour tissue (1.03 mM). HESW application resulted in a significant decrease in blood flow in tumours and adjacent tissue with the lowest values obtained 3 h after treatment. To illustrate the pattern of flow changes, which was clear despite intraindividual variability, blood flow in individual untreated tumours and treated tumours is depicted in Figure 2a . Three hours after treatment blood flow fell to background level in the majority of tumours. Values of the perfusion were significantly elevated 24 h after treatment (P <0.001). The reduction of blood flow in adjacent tissue following HESW was less pronounced (Figure 2b) .
ATP concentrations significantly declined in treated tumours (P<0.001) with minimum values 3 h after therapy (Figure 3a) . Subsequently, ATP concentrations increased without reaching control levels. Adjacent tissue showed decreased ATP concentrations at 3, 12 and 24 h after HESW (Figure 3b) . Thus, HESW induced corresponding changes in blood flow and ATP in both tumour and adjacent normal tissue. The effects seen were less dramatic in normal tissue as compared to tumour. Table I Blood flow and ATP concentration in untreated tumours (control), treated tumours and the corresponding adjacent normal tissue at 3 (n = 6), 12 (n = 6) and 24 h (n = 6) after application of 700 multifocally focused HESW Blood flow ATP (ml 100 g -' min-') (mM) therapy. In addition, the effect of HESW on tumour growth has been investigated. We observed tumour ischemia and ATP concentrations reduced to background level 3 h after HESW therapy. Thereafter, values of both parameters increased. Twenty-four hours following treatment tumour Goetz et al. (1987) , who investigated the effects of HESW on the A-Mel-3 tumour implanted into a chamber preparation. These findings may be explained by a higher sensitivity of the tumour vasculature to physical disturbances (Ribbert, 1904; Goetz et al., 1987; Chaplin, 1991 (Clayman et al., 1991) . In vivo these mechanisms may more likely develop within blood as a fluid medium (Clayman et al., 1991) . Studies on the effects of HESW in solid tumours in vivo have demonstrated that poorly perfused tumours have a reduced susceptibility to HESW (Oosterhof et al., 1990b) . This is further evidence for an ischemia related cell injury as an important mechanism of the HESW effects on solid tumours. A higher fraction of perfusion-and diffusion-limited chronically hypoxic cells has to be expected in poorly vascularised tumours (Kallinowski et al., 1989) . Thus cells from poorly perfused tumours are probably adapted to the chronic nutrient deficiency and might for that reason longer withstand acute, ischemia related hypoxia.
Our results have shown that tumour growth was significantly delayed even when 700 HESW were multifocally applied only once, whereas most investigators observed tumour growth delay following repeatedly treatments on consecutive days with high amounts i.e. 500 to 8000 HESW (Weiss et al., 1990; Hoshi et al., 1991) . The slight increase in volume doubling time of the regrowing tumours may be caused by an enhanced synthesis rate of the tumour cells upon reoxygenation (Wilson et al., 1989 (Weiss et al., 1990) . Blood vessels of the fast growing tumour A-Mel-3 proliferate mainly in the tumour margin, whereas necrotic, avascular areas appear in the central part (Endrich et al., 1982) . In skin muscle adjacent to the subcutaneously implanted tumour infiltrating tumour cells can be observed upon histological investigations. The focal region of the XLI lithotripter, which is defined by the isobar representing 50% of maximum pressure, is known to be 5 mm in diameter and 22 mm in longitudinal axis (Muller, 1990) . Thus only a part of HESW energy is delivered to the periphery of tumours 6-9 mm in diameter when HESW are focused on the tumour centre, which is known to be nutritionally and metabolically deprived. This fact could explain that only a slight, if any, effect of HESW treatment on solid tumours has been observed by investigators that applied HESW only to the tumour centre, especially when larger tumours were treated (Oosterhof et al., 1990b) . The advantages of the multifocal application mode may be of particular importance when larger tumour volumes are to be treated and higher dosages of HESW are required. However, the calculation of mode and dosage of HESW treatment of larger tumours is, as yet, completely unknown. We conclude that both direct cytotoxicity and ischemiainduced cell injury contribute to the effects of HESW to tumours in vivo. The reduction of tumour blood flow has to be taken into consideration when HESW are used in further studies in multi-fraction treatments or as a combined treatment modality. Tumour 
